CHA is proud to be helping the scientific community realize the potential of these contributors by providing them with a platform to receive the feedback and support that they need to increase their chances of commercial success.
Needham, MA (PRWEB) March 10, 2014
Announcing the launch of a new program in the life science and health care industries, which will help evaluate and rank new technologies and services via an end-user process. The Signature Award™, developed based on recommendations from the pharmaceutical and biotech industries, follows best-in-class principles to better inform decision-makers and users, investors, and those who are trying to commercialize their science.
The Signature Award program gives technology and service providers an opportunity to present their innovations to key decision-makers in the industry.
arGEN-X, a past Signature Award winner, has seen considerable success as a result of having participated in this ground-breaking program. "Being a Signature Award winner has catapulted arGEN-X from believing in the uniqueness of our technology to seeing it acknowledged as such by our customers and future partners," said Debbie Allen, PhD, Senior Director of Business Development at arGEN-X.
Interested parties apply to the program as a commercial or an academic technology or service provider. All applicants receive qualitative and quantitative feedback from the panel of Subject Matter Experts (SMEs). Based on the feedback, each technology or service is placed into one of four categories. This classification is based on the strength of their value proposition and level of market readiness. Participants obtain valuable validation which can support their market penetration efforts and/or investor relations goals.
Tim Van Hauwermeiren, CEO of arGEN-X, says that, “The Signature Award has enabled arGEN-X to establish the SIMPLE Antibody™ brand as the leader in tackling high value but complex antibody disease targets. We are now ideally positioned to leverage the power of our proprietary suite of antibody technologies through the creation of truly differentiated antibody products.”
The General Manager of CHA, Dawn Van Dam, stated that, “the industry has progressed as much as it has due to new science and the innovative thinkers who are constantly finding new solutions. CHA is proud to be helping the scientific community realize the potential of these contributors by providing them with a platform to receive the feedback and support that they need to increase their chances of commercial success.”
Nearly a decade ago, CHA received a request from leaders in the biopharmaceutical industry to form the Technology Evaluation Consortium™ (TEC™) and the Drug Safety Executive Council™. The success of the TEC, and the resulting demand for evaluating the vast number of technologies and services available today in life sciences and health care, brought forth the creation of the Signature Award program.
Additional information is available here. Applications can be obtained by contacting Dawn Van Dam.
About Cambridge Healthtech Associates™
Cambridge Healthtech Associates (CHA) enables clients in the life sciences and health care industries to accelerate the progression from scientific innovation to commercial success. CHA offers a refreshing, collaborative take on the standard marketing model by offering consulting, technology evaluations and marketing communication services, alongside an unparalleled understanding of industry dynamics and first-hand experience (http://www.chacorporate.com).
Cambridge Healthtech Associates. Transforming science into commercial success.